Aditxt Inc.

Company Overview

Business Model: Aditxt, Inc. operates as an innovation platform focused on discovering, developing, and deploying health innovations. The Company aims to transform promising innovations into products and services by engaging a broad ecosystem of research institutions, industry partners, and shareholders. Its primary revenue generation mechanisms are expected to stem from the commercialization of its therapeutic and diagnostic product candidates, though it has generated minimal revenue to date.

Market Position: Aditxt, Inc. is an early-stage company primarily engaged in research and development within the biotechnology and life sciences sectors. It aims to establish unique positions in immune modulation therapeutics through Adimune, Inc. and early disease detection diagnostics through Pearsanta, Inc. Adimune, Inc.'s Apoptotic DNA Immunotherapy™ (ADI™) platform is designed to induce immune tolerance, a novel approach compared to existing immune suppression methods. Pearsanta, Inc.'s Mitomic® Technology platform focuses on mitochondrial DNA-based molecular tests for early cancer and endometriosis detection, leveraging a CLIA-certified, CAP-accredited, and NYS CLEP-approved laboratory facility. The Company acknowledges operating in highly competitive industries with established multinational pharmaceutical and biotechnology companies.

Recent Strategic Developments:

• Adimune, Inc. Therapeutic Programs: Completed all preclinical studies for ADI-100, supporting its potential effectiveness in restoring durable tolerance for conditions like type-1 diabetes (T1D) and psoriasis. Good Manufacturing Practices (GMP) clinical-grade drug substances for ADI-100 have been manufactured. Engaged a Contract Research Organization (CRO) for planned clinical trials in Germany for psoriasis and T1D. Collaborating with the Mayo Clinic to prepare an Investigational New Drug (IND) package for U.S. Food and Drug Administration (FDA) submission, with a pre-IND meeting expected in Q2 2026. A human trial for Stiff Person Syndrome (SPS) is expected to begin in 2026 with 10-20 patients.
• Pearsanta, Inc. Diagnostic Programs: Acquired assets of MDNA Life Sciences Inc. in January 2024, including the Mitomic® Technology platform, patents, and intellectual property, to advance mtDNA-based biomarker discovery. Developing Mitomic® Prostate Test (MPT™) for prostate cancer diagnosis and Mitomic Endometriosis Test (MET™) for endometriosis detection. Discovered mtDNA-based biomarkers associated with ovarian and lung cancers, with intentions to pursue biomarker identification for pancreatic, liver, breast, stomach, esophageal, and colorectal cancers. Acquired patents related to Adductomics Technology on March 21, 2025, for comprehensive assessment of DNA adducts, with development anticipated over the next two to three years. Terminated the exclusive worldwide sub-license for AditxtScore™ technology with Pearsanta, Inc. on September 23, 2025, replacing it with a non-exclusive licensing agreement for SARS-CoV-2 antibody evaluation as of December 30, 2025.
• Adifem, Inc. and Evofem Biosciences, Inc. Merger Termination: The planned acquisition of Evofem Biosciences, Inc. through its subsidiary Adifem, Inc. was terminated on October 20, 2025, due to the end date passing and failure to obtain Evofem Biosciences, Inc. shareholder approval. Aditxt, Inc. retains its holdings of Evofem F-1 Preferred Stock, convertible notes, and Evofem Warrants.
• Acquisition of Ignite Proteomics, LLC (Subsequent Event): On March 11, 2026, Aditxt, Inc. acquired 100% of the equity interests in Ignite Proteomics, LLC for 36,000 shares of newly created Series A-2 Convertible Preferred Stock, valued at $36,000,000.
• Reverse Stock Splits: Effectuated a 1-for-40 reverse stock split on October 2, 2024, a 1-for-250 reverse stock split on March 14, 2025, a 1-for-113 reverse stock split on November 3, 2025, and a 1-for-8 reverse stock split on March 9, 2026 (subsequent event), primarily to regain Nasdaq compliance.

Geographic Footprint: Aditxt, Inc. is headquartered in Mountain View, California. Its primary operational regions include Mountain View, California (office and laboratory space) and Richmond, Virginia (CLIA-certified, CAP-accredited, and NYS CLEP-approved laboratory facility for Pearsanta, Inc.). Adimune, Inc. has engaged with a Contract Research Organization (CRO) for planned clinical trials in Germany.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: 8.4%
• Operating Margin: -612.5%
• Net Margin: -1339.2%

Investment in Growth:

• R&D Expenditure: $3.194 million (100,000.0% of revenue)
• Capital Expenditures: $0.014 million
• Strategic Investments:
  • Investment in Evofem Biosciences, Inc. convertible notes receivable and warrants: $2.425 million in 2025.
  • Acquisition of patents for Adductomics Technology by Pearsanta, Inc.: $0.010 million in 2025.

Business Segment Analysis

Adimune, Inc.

Key Growth Drivers:

• Advancement of Apoptotic DNA Immunotherapy™ (ADI™) platform, particularly ADI-100, for immune modulation.
• Successful completion of preclinical studies for ADI-100 in type-1 diabetes (T1D), psoriasis, and autoimmune diseases of the central nervous system (CNS).
• Progress towards human clinical trials for ADI-100 in Germany (psoriasis and T1D) and the U.S. (Stiff Person Syndrome, SPS, and T1D) in collaboration with the Mayo Clinic.
• Proprietary approach of in-body induction of apoptosis to promote specific tissue tolerance, aiming to reduce the need for broad immune suppression.

Product Portfolio:

• Apoptotic DNA Immunotherapy™ (ADI™) Platform: Nucleic acid-based technology designed to selectively suppress immune cells involved in attacking self or transplanted tissues.
• ADI-100: First product candidate from the ADI™ platform, designed to tolerize against glutamic acid decarboxylase (GAD), implicated in T1D, psoriasis, and CNS autoimmune diseases.
• New product launches or major updates: GMP clinical-grade drug substances for ADI-100 have been manufactured, and final drug product formulation is underway for stability testing and clinical trials.

Market Dynamics:

• Targets significant unmet medical needs in autoimmune diseases and organ transplantation, aiming to overcome side effects of broad immune suppression.
• Focus on rare diseases like Stiff Person Syndrome (SPS) (estimated incidence: one in one million individuals).
• Competitive positioning is based on a unique "in-body induction of apoptosis" approach.

Pearsanta, Inc.

Key Growth Drivers:

• Leveraging the Mitomic® Technology platform for early disease detection based on mitochondrial DNA (mtDNA) mutations.
• Development of molecular tests for high-clinical need cancers and endometriosis.
• Acquisition of Adductomics Technology patents to expand into DNA adduct detection for cancer risk assessment.

Product Portfolio:

• Mitomic® Technology Platform: Utilizes unique properties of mtDNA to detect disease through non-invasive, blood-based liquid biopsies.
• Mitomic® Prostate Test (MPT™): In development as a blood-based assay to quantify the 3.4kb mtDNA deletion, potentially aiding in prostate cancer diagnosis.
• Mitomic Endometriosis Test (MET™): In development as a blood-based assay to quantify mtDNA deletions associated with endometriosis.
• Adductomics Technology: Acquired patents for detection and analysis of DNA adducts, aiming to provide insights into DNA damage before mutations occur, with diagnostic kits planned for development over the next two to three years.
• AditxtScore™: Non-exclusive licensing agreement for evaluating levels of antibodies and neutralizing antibodies to SARS-CoV-2.

Market Dynamics:

• Aims to address challenges in early cancer detection and delayed diagnosis in endometriosis.
• Operates a high-complexity, CLIA-certified, CAP-accredited, and NYS CLEP-approved laboratory in Richmond, Virginia.
• Plans to license distribution rights through U.S. and international business partners for commercialization of Mitomic® Technology tests, pending regulatory approvals.

Adivir, Inc.

Key Growth Drivers:

• Dedicated to advancing clinical and commercial development of innovative products for infectious disease and population health.
• Focus on building a portfolio of antiviral and other antimicrobial solutions targeting life-threatening viral infections and emerging pathogens.

Market Dynamics:

• Strategic objective to improve treatment access and outcomes where existing options are limited or inadequate.
• Aims to contribute to global healthcare challenges posed by infectious diseases.
• Terminated the Arrangement Agreement with Appili Therapeutics, Inc. effective May 31, 2025, incurring a $1,250,000 termination fee (with $750,000 remaining as of December 31, 2025).

Adifem, Inc.

Key Growth Drivers:

• Formed in April 2024 for strategic expansion into women's health.
• Commitment to investing in therapeutic areas with significant unmet medical need and opportunity for patient impact.

Market Dynamics:

• Initially formed in connection with a proposed acquisition of Evofem Biosciences, Inc., which was terminated on October 20, 2025.
• Despite the termination, Aditxt, Inc.'s commitment to women's health remains a strategic objective.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: $0
• Dividend Payments: $0
• Dividend Yield: 0.0%
• Future Capital Return Commitments: Not disclosed.

Balance Sheet Position:

• Cash and Equivalents: $3.199 million
• Total Debt: $1.855 million (current notes payable, net of discount)
• Net Cash Position: $1.344 million
• Credit Rating: Not disclosed.
• Debt Maturity Profile: As of December 31, 2025, the November Loan Agreement ($0.289 million principal), January Loan Agreement ($0.752 million principal), and May 2025 Note ($0.814 million principal) were in technical default or default status.

Cash Flow Generation:

• Operating Cash Flow: $(25.688) million
• Free Cash Flow: $(25.702) million
• Cash Conversion Metrics: Significant negative operating and free cash flow indicate high cash burn.

Operational Excellence

Production & Service Model: Aditxt, Inc. operates a hybrid model, relying on both in-house capabilities and third-party contract manufacturers and research organizations. Adimune, Inc. engages qualified contract manufacturers for GMP clinical-grade drug substance production and another contract manufacturer for final drug product formulation, and collaborates with Contract Research Organizations (CROs) for clinical trial management. Pearsanta, Inc. operates a state-of-the-art, high-complexity, CLIA-certified, CAP-accredited, and NYS CLEP-approved laboratory facility in Richmond, Virginia, optimized for molecular biology capabilities and automated processes.

Supply Chain Architecture: Key Suppliers & Partners:

• Contract Manufacturers (Adimune, Inc.): Qualified contract manufacturers for drug substance and drug product manufacturing.
• Contract Research Organizations (Adimune, Inc.): Engaged for managing clinical trials and site selection in Germany.
• Loma Linda University: Exclusive worldwide licensor of ADI™ nucleic acid-based technology.
• Leland Stanford Junior University: Exclusive worldwide licensor of a patent concerning a method for detection and measurement of specific cellular responses (FlowSpot technology, underlying AditxtScore™).
• Mayo Clinic: Partner for preparing the IND package for FDA submission and advancing clinical studies for autoimmune diseases.

Facility Network:

• Manufacturing: Not explicitly detailed beyond reliance on third-party contract manufacturers.
• Research & Development: Headquarters and R&D in Mountain View, CA.
• Distribution: Pearsanta, Inc. operates a CLIA-certified, CAP-accredited, and NYS CLEP-approved laboratory in Richmond, Virginia.

Operational Metrics:

• Depreciation Expense: $0.269 million (2025) vs $0.614 million (2024)
• Amortization of Intangible Assets: $0.003 million (2025) vs $0.003 million (2024)

Market Access & Customer Relationships

Go-to-Market Strategy: Distribution Channels:

• Direct Sales: Not explicitly detailed.
• Channel Partners: Pearsanta, Inc. plans to license distribution rights through various agreements with U.S.-based and international business partners for commercializing its Mitomic® Technology.
• Digital Platforms: Not explicitly mentioned for sales, but AditxtScore™ is designed to enable individuals and healthcare providers to understand and monitor immune profiles.

Customer Portfolio: Enterprise Customers:

• Strategic Partnerships: Mayo Clinic for clinical studies.
• Customer Concentration: Not explicitly disclosed, but the business model relies on adoption by the medical community, including physicians, patients, and health care payors.

Geographic Revenue Distribution:

• United States: 100.0% of total revenue
• Growth Markets: Not explicitly detailed.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: Aditxt, Inc. operates in highly competitive and rapidly changing biotechnology and life sciences industries, characterized by continuous technological advances and scientific discoveries. The markets for its product candidates are intensely competitive, with a mix of large multinational pharmaceutical companies, specialized biotechnology firms, and research institutions. Key Trends Driving Industry Evolution:

• Demand for novel immune modulation therapies with fewer side effects than broad immunosuppression.
• Growing need for early disease detection through non-invasive diagnostics.
• Increasing focus on personalized medicine and comprehensive immune profiling.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors:

• Multinational Pharmaceutical Companies: Larger, more established companies with greater financial, technical, and human resources, and existing market dominance in therapeutic and diagnostic areas.
• Specialized Biotechnology Companies: Other firms developing competitive product candidates and processes.
• Universities and Research Institutions: Engaged in developing competitive products and processes.

Emerging Competitive Threats: New entrants and disruptive technologies in immune modulation and molecular diagnostics, as well as alternative solutions that may be safer, more effective, more widely used, or less expensive.

Competitive Response Strategy: Aditxt, Inc.'s strategy involves developing proprietary, novel technologies to address unmet medical needs and differentiate its offerings. This includes pursuing regulatory approvals and establishing strategic partnerships for development and commercialization.

Risk Assessment Framework

Strategic & Market Risks

Market Dynamics:

• Early-Stage Commercialization: The Company has generated no significant revenue from commercial sales to date, and future profitability is uncertain. Success depends on obtaining regulatory approvals and achieving market acceptance, which is a lengthy, expensive, and uncertain process.
• Competition: Operates in highly competitive industries with larger, more established companies that have greater resources, potentially leading to pricing pressure, reduced margins, or failure to achieve market acceptance.
• Customer Adoption: Customers in the sector can be cautious in adopting new products, potentially delaying adoption.
• Technology Disruption: Risk that technological advances by competitors could render Aditxt, Inc.'s technologies obsolete.
• Product Liability: Potential for liability and remediation claims if products cause injury or are found unsuitable, even after regulatory approval.

Operational & Execution Risks

Supply Chain Vulnerabilities:

• Third-Party Reliance: Relies on third parties for manufacturing and distribution, posing risks related to quality, timeliness, cost, and adequate resource allocation.
• Supplier Dependency: Dependence on specific licensors (Loma Linda University, Leland Stanford Junior University) for core technologies, with licenses revocable if certain payments or milestone deadlines are not met.
• Capacity Constraints: Potential difficulties in scaling up production, including issues with yields, quality control, personnel shortages, and process controls.

Internal Control Deficiencies:

• Material Weaknesses: As of December 31, 2025, the Company did not maintain adequate controls over the financial reporting process, did not have sufficient resources or independent expertise for complex accounting matters, and lacked sufficient procedures for review and approval of journal entries and account reconciliations. These led to material misstatements that were corrected.

Financial & Regulatory Risks

Market & Financial Risks:

• Going Concern Doubt: The Company's financial situation, including significant net losses ($42.787 million in 2025) and negative operating cash flow ($25.688 million in 2025), raises substantial doubt about its ability to continue as a going concern.
• Need for Additional Capital: Requires significant additional capital to fund operations and clinical studies; future funding may not be available on acceptable terms or at all, potentially leading to delays or termination of development efforts.
• Dilution Risk: Future equity or convertible debt financings could result in significant dilution to existing stockholders.
• Nasdaq Delisting Risk: Non-compliance with Nasdaq listing rules (e.g., minimum stockholders' equity, minimum bid price, proposed minimum market capitalization) could lead to delisting, reducing liquidity and market price of common stock.
• Debt Default: Several notes payable were in technical default or default status as of December 31, 2025.
• Lease Default: In default on the Richmond, Virginia lease for an outstanding security deposit of $159,375 as of December 31, 2025.

Regulatory & Compliance Risks:

• Regulatory Approval Process: The regulatory approval process for product candidates is expensive, time-consuming, and uncertain, with no guarantee of approval or successful commercialization.
• CLIA Certification: Reliance on CLIA certification and state laboratory licenses for diagnostic testing; loss of certification or licenses would severely harm the business.
• Extensive Regulation: Subject to numerous and expanding laws and regulations (e.g., accounting, anti-bribery, consumer protection, data security, product liability), with non-compliance potentially resulting in substantial penalties.
• Government Funding Rights: Some intellectual property may be subject to federal regulations (e.g., Bayh-Dole Act "march-in" rights, manufacturing preference for U.S. industry) due to government funding, potentially limiting exclusive rights or ability to contract with non-U.S. manufacturers.

Geopolitical & External Risks

Geopolitical Exposure: Not explicitly detailed.

Trade Relations: Not explicitly detailed.

Sanctions & Export Controls: Not explicitly detailed.

Innovation & Technology Leadership

Research & Development Focus: Aditxt, Inc. is focused on advancing health innovations through its subsidiaries: Adimune, Inc. (immune modulation therapeutics), Pearsanta, Inc. (molecular diagnostics for early disease detection), and Adivir, Inc. (antiviral and antimicrobial solutions).

Core Technology Areas:

• Immune Modulation (Adimune, Inc.): ADI™ nucleic acid-based technology designed to induce therapeutically induced immune tolerance.
• Mitochondrial DNA-based Diagnostics (Pearsanta, Inc.): Mitomic® Technology platform identifies mutated mtDNA for early detection of diseases.
• DNA Adduct Detection (Pearsanta, Inc.): Adductomics Technology focuses on detecting chemically modified nucleotides as early indicators of genomic instability and increased cancer risk.
• Immune Profiling (AditxtScore™/FlowSpot): Technologies licensed from Leland Stanford Junior University for comprehensive immune system profiling.

Innovation Pipeline:

• ADI-100: Completed preclinical studies, with GMP clinical-grade drug substance manufactured, and preparing for U.S. FDA IND submission and clinical trials in Germany and the U.S. (SPS, T1D) in 2026.
• Mitomic® Prostate Test (MPT™) & Mitomic Endometriosis Test (MET™): Currently in development.
• Adductomics Technology: Early-stage development with a roadmap for further validation and commercial diagnostic kits within two to three years.
• Biomarker Identification: Ongoing discovery of mtDNA-based biomarkers for various cancers.

Intellectual Property Portfolio:

• Patent Strategy: Relies on exclusive worldwide licenses for core technologies (ADI™ from Loma Linda University, FlowSpot from Leland Stanford Junior University) and owned patents (Mitomic® Technology, Adductomics Technology).
• Licensing Programs: Engages in royalty-bearing license agreements for commercialization rights.
• IP Litigation: Subject to risks of infringement claims, challenges to patent validity, and potential misappropriation claims.

Technology Partnerships:

• Loma Linda University: Exclusive worldwide license for ADI™ technology.
• Leland Stanford Junior University: Exclusive worldwide license for FlowSpot technology.
• Mayo Clinic: Clinical trial agreement for advancing studies in autoimmune diseases.

Leadership & Governance

Executive Leadership Team

Leadership Continuity: The executive team includes several long-tenured members, with the CEO and Chief Innovation Officer serving since inception.

Board Composition: The Board of Directors includes Amro Albanna, Shahrokh Shabahang, D.D.S., MS, Ph.D., Brian Brady, Charles Nelson, and Sylvia Hermina. Brian Brady, Charles Nelson, and Sylvia Hermina are considered "independent" under Nasdaq listing rules. The Board has established Audit, Compensation, and Nominating and Corporate Governance Committees, all composed of independent directors. Mr. Brady chairs the Audit Committee and is an Audit Committee financial expert. Mr. Nelson chairs the Compensation Committee. Ms. Hermina chairs the Nominating and Corporate Governance Committee.

Human Capital Strategy

Workforce Composition:

• Total Employees: 26 full-time employees as of December 31, 2025.
• Skill Mix: Team comprises experts from scientific and commercial backgrounds with experience in biotech startups, biopharmaceutical product development, clinical trial design, and company management.

Talent Management: Acquisition & Retention:

• Hiring Strategy: Relies on attracting and retaining highly skilled personnel, potentially requiring competitive compensation and incentives.
• Employee Value Proposition: Compensation philosophy includes base salary, annual performance-based bonuses (for executives), and equity awards through the 2021 Omnibus Equity Incentive Plan.

Diversity & Development:

• Culture & Engagement: Relations with employees are considered good.

Environmental & Social Impact

No material information explicitly stated in the filing.

Business Cyclicality & Seasonality

Demand Patterns:

• Seasonal Trends: The decrease in revenue and cost of goods sold in 2025 compared to 2024 was attributed to a decrease in AditxtScore™ orders due to decreased COVID testing, indicating sensitivity to public health crises and related testing demand.
• Economic Sensitivity: The Company's business and operations are sensitive to general business and economic conditions.
• Industry Cycles: The biotechnology and life sciences industries are characterized by rapid change, which can influence demand and product development cycles.

Planning & Forecasting: Not explicitly detailed.

Regulatory Environment & Compliance

Regulatory Framework: Industry-Specific Regulations:

• FDA Approval: Product candidates require FDA approval in the U.S. and corresponding agency approvals in foreign countries for marketing.
• CLIA, CAP, NYS CLEP: Pearsanta, Inc.'s laboratory is CLIA-certified, CAP-accredited, and NYS CLEP-approved, enabling it to perform high-complexity testing.
• International Compliance: Adimune, Inc. has engaged with regulatory agencies in Germany for planned clinical trials.
• Extensive Regulation: Subject to numerous and expanding laws and regulations (e.g., accounting, anti-bribery, consumer protection, data security, product liability), with non-compliance potentially resulting in substantial penalties.
• Government Funding Rights: Some intellectual property may be subject to federal regulations (e.g., Bayh-Dole Act "march-in" rights, manufacturing preference for U.S. industry) due to government funding.

Legal Proceedings:

• Vertalo, Inc. Lawsuit: On February 3, 2026, Vertalo, Inc. filed a lawsuit against Aditxt, Inc. for alleged breach of contract, seeking $300,000 in unpaid fees, warrants for 6,250 common shares, $26,000 in travel costs, and at least $500,000 in additional damages, plus attorneys' fees and interest. Aditxt, Inc. disputes the allegations and intends to defend vigorously.
• General Litigation: The Company is involved in various claims and legal proceedings in the ordinary course of business, but does not believe the final outcome of current matters will have a material adverse effect on its financial position or results of operations.

Tax Strategy & Considerations

Tax Profile:

• Effective Tax Rate: 0.0% (due to net losses and full valuation allowance against deferred tax assets).
• Geographic Tax Planning: Files tax returns in the United States, California, Virginia, and New York.
• Tax Reform Impact: Subject to the 2017 Tax Cuts and Jobs Act (TCJA) provisions regarding net operating loss carryforwards (indefinite carryover, 80% taxable income limitation for post-2017 losses).

Insurance & Risk Transfer

Risk Management Framework:

• Insurance Coverage: Maintains product liability insurance at levels believed to be sufficient and consistent with industry standards. Also maintains cybersecurity insurance.
• Risk Transfer Mechanisms: Not explicitly detailed beyond insurance.